USANA Health Sciences reported a decrease in net sales to $233 million compared to $274 million in the prior year quarter. Diluted EPS also decreased to $0.78 versus $1.36 in the third quarter of 2021. The company revised its fiscal year 2022 net sales and diluted EPS outlook to $955 million to $975 million and $3.15 to $3.40, respectively.
Third quarter net sales were $233 million, a 15% decrease compared to the prior-year quarter.
Third quarter diluted EPS totaled $0.78, a 43% decrease compared to the third quarter of 2021.
The company generated $29 million in operating cash flow and ended the quarter with $247 million in cash and cash equivalents, remaining debt-free.
Management is evaluating and executing several short-term initiatives to regain momentum, including new incentives and increased in-person communications.
The Company is revising its net sales and earnings per share outlook for fiscal year 2022 due to lower Active Customer base and continued expectations of COVID-related, inflationary and economic challenges.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance